Kevin Martin, MD
Pulmonary Disease · Worcester, MANPI 1124107123
Payments from drug & device makers
Across 239 payments — averaging $60.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$2K
- GSK$556
- Sanofi$477
- Regeneron Healthcare Solutions, Inc.$307
- Merck$273
- plus $3K from 36 others
What the payments were for
- Travel & lodging$1,2439%
- Food & beverage$6,07642%
- Education$7,13149%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $8,325 |
| AstraZeneca(2 entities) | 77 | $2,010 |
| GSK | 24 | $556 |
| Sanofi | 19 | $477 |
| Regeneron Healthcare Solutions, Inc. | 13 | $307 |
| Merck | 11 | $273 |
| Eisai Inc. | 10 | $267 |
| Bayer | 7 | $214 |
| Exelixis Inc. | 5 | $202 |
| Boehringer Ingelheim | 7 | $167 |
| Actelion Pharmaceuticals US, Inc. | 2 | $162 |
| Amgen | 4 | $123 |
| Mirati Therapeutics, Inc. | 3 | $104 |
| Inspire Medical Systems, Inc. | 1 | $98 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| Incyte Corporation | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Johnson & Johnson(2 entities) | 3 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| AbbVie | 2 | $67 |
| Geron Corporation | 2 | $61 |
| Sobi, Inc | 2 | $58 |
| Gilead | 2 | $53 |
| Karyopharm Therapeutics Inc. | 2 | $49 |
| Novartis | 2 | $47 |
| Pfizer | 2 | $44 |
| Circassia Inc. | 1 | $36 |
| Insmed, Inc. | 1 | $34 |
| Seagen Inc. | 1 | $30 |
| Beigene USA, Inc. | 1 | $29 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| CTI Biopharma Corp. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Alcresta Therapeutics, Inc. | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $17 |
| Covidien LP | 1 | $17 |
| Covis Pharma GmbH | 1 | $17 |
| United Therapeutics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,179
- BREZTRI$123
- UPTRAVI$122
- OPSUMIT$122
- FASENRA$110
How this compares
$14,451 in reported general payments places this provider in the 80th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 420 | $336,517 |
| CaystonAztreonam Lysine | 16 | $195,145 |
| NucalaMepolizumab | 26 | $193,705 |
| Dupixent PenDupilumab | 35 | $123,536 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 186 | $120,902 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $101,544 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $78,562 |
| TezspireTezepelumab-Ekko | 14 | $61,566 |
| Spiriva RespimatTiotropium Bromide | 91 | $53,930 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 52 | $37,301 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $30,534 |
| Incruse ElliptaUmeclidinium Bromide | 66 | $30,086 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 52 | $23,387 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $20,846 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 534 | $17,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $556 | $775,577909 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort | $2,010 | $207,342270 claims |
| GileadCayston | $53 | $195,14516 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $167 | $121,764203 claims |
| PfizerEliquis | $44 | $12,31322 claims |
| MerckDulera | $273 | $12,15626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Worcester
- Yaron GoldmanWorcester$843K
- Fernando MartinezWorcester$375K
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Curtis MelloNorth Dartmouth$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.